Zhengye Biotechnology Holding (ZYBT) Accounts Payables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Accounts Payables for 3 consecutive years, with $6.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Accounts Payables rose 3.75% year-over-year to $6.2 million in Q4 2025; TTM through Dec 2025 was $6.2 million, a 3.75% increase from a year earlier, with the FY2025 full-year figure at $6.3 million, up 6.98% from the prior year.
• Accounts Payables was $6.2 million for Q4 2025 at Zhengye Biotechnology Holding, up from $6.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $6.3 million in Q4 2023 and troughed at $6.0 million in Q2 2025.
• A 3-year average of $6.1 million and a median of $6.1 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables dropped 5.69% in 2024 and increased 3.75% in 2025, its largest moves.
• Over 3 years, Accounts Payables stood at $6.3 million in 2023, then declined by 5.69% to $6.0 million in 2024, then grew by 3.75% to $6.2 million in 2025.
• The last three Accounts Payables figures came in at $6.2 million (Q4 2025), $6.0 million (Q2 2025), and $6.0 million (Q4 2024), per Business Quant data.